Molecular BiologybioRxivPreprint
Resolving the pharmacological redox-sensitivity of SARS-CoV-2 PLpro in drug repurposing screening enabled identification of the competitive GRL-0617 binding site inhibitor CPI-169
Maria Kuzikov, Stefano Morasso, Jeanette Reinshagen…·Andrea Zaliani
The paper identifies CPI-169 as a competitive inhibitor of SARS-CoV-2 PLpro that targets the same binding site as GRL-0617, through a drug repurposing screening approach that accounts for redox-sensitivity.
2 citations